Arcturus Therapeutics, Inc.
10628 Science Center Drive
Suite 250
San Diego
CA
92121
United States
Website: https://arcturusrx.com/
Email: info@arcturusrx.com
About Arcturus Therapeutics, Inc.
Arcturus Therapeutics is a global late-stage clinical messenger RNA medicines and vaccines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics.
CONNECT
114 articles about Arcturus Therapeutics, Inc.
-
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
2/26/2024
Arcturus Therapeutics Holdings Inc. today announced that the Company will present at a Fireside Chat hosted by Barclays 26th Annual Global Healthcare Conference.
-
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
2/20/2024
Arcturus Therapeutics Holdings Inc. today announced that it will release its financial results for the quarter and year ended December 31, 2023 after the market close on Thursday, March 7.
-
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster - February 5, 2024
2/5/2024
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the results of a follow-up analysis of a Phase 3 study evaluating a booster dose of ARCT-154, the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine, compared to a conventional mRNA COVID-19 vaccine.
-
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
12/21/2023
Global biotechnology leader CSL and Arcturus Therapeutics announced the publication in Lancet Infectious Diseases of a Phase 3 study showing that a booster dose of ARCT-154, a novel, self-amplifying messenger RNA vaccine, elicited a numerically higher immune response against the original Wuhan-Hu-1 virus strain, and a superior immune response against Omicron BA.4/5 subvariant of SARS-CoV-2 virus compared to a booster dose of the conventional mRNA vaccine Comirnaty®.
-
Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/4/2023
Arcturus Therapeutics Holdings Inc. today announced that Joseph Payne, President & Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, on Tuesday, January 9, 2024, at 3:00 p.m. Pacific Time.
-
Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis
11/27/2023
Arcturus Therapeutics Holdings Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the Company’s product candidate ARCT-032 to treat cystic fibrosis (CF).
-
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese Government
10/4/2023
Arcturus Therapeutics Holdings Inc. announced today that ARCALIS, Arcturus’ manufacturing joint venture in Japan to support the production of mRNA vaccines and therapeutics, has been selected by the Japanese Ministry of Economy, Trade and Industry to receive additional financial support to construct a DNA template manufacturing facility along with new state-of-the-art equipment.
-
CF Foundation Invests Up to $9 Million in Arcturus Therapeutics to Develop a Messenger RNA Therapy
9/26/2023
The Cystic Fibrosis Foundation is investing up to $9 million in additional funds in Arcturus Therapeutics to test an inhaled messenger RNA (mRNA) therapy that could treat the underlying cause of cystic fibrosis in all people living with the disease, including those with two copies of rare and nonsense mutations.
-
Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis
9/26/2023
Arcturus Therapeutics Holdings Inc. (the announced today that Arcturus and the Cystic Fibrosis Foundation (CF Foundation) have extended their ongoing agreement.
-
Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
9/5/2023
Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19.
-
Arcturus Therapeutics to Attend Upcoming Investor Conferences - August 17, 2023
8/17/2023
Arcturus Therapeutics Holdings Inc. announced that the Company will participate in the following investor conferences.
-
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government
8/14/2023
Arcturus Therapeutics Holdings Inc. announced that ARCALIS Co., Ltd., its manufacturing joint venture in Japan to support the production of mRNA vaccines and therapeutics, has been awarded $115 million in two separate grants from the Japanese government.
-
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency
6/1/2023
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency.
-
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023
4/26/2023
Arcturus Therapeutics Holdings Inc. (the today announced that it will release its financial results for the quarter ended March 31, 2023 after the market close on Tuesday, May 9 and will also host a conference call and webcast at 4:30 pm.
-
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023
3/7/2023
Arcturus Therapeutics Holdings Inc. today announced that it will release its financial results for the quarter and year ended December 31, 2022 after the market close on Tuesday, March 28 and will also host a conference call and webcast at 4:30 p.m. Eastern Time on March 28, 2023.
-
Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis
1/31/2023
Arcturus Therapeutics Holdings Inc. today announced that the Clinical Trial Application (CTA) for ARCT-032, an inhaled investigational mRNA medicine to treat cystic fibrosis (CF), received approval to proceed into a Phase 1 First-in-Human study in New Zealand.
-
Arcturus Appoints John Markels, Ph.D. to its Board of Directors
12/13/2022
Arcturus Therapeutics Holdings Inc. today announced that is has appointed John Markels, Ph.D., an accomplished pharmaceutical executive with over 35 years of industry experience, to its Board of Directors.
-
CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics
12/12/2022
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that its subsidiary, CSL Seqirus, finalized its global collaboration and license agreement with Arcturus Therapeutics Holdings Inc ("Arcturus Therapeutics"; NASDAQ: ARCT).
-
Arcturus Therapeutics to Present at the Following Investor Conferences in November 2022
11/7/2022
Arcturus Therapeutics Holdings Inc., a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, announced that the Company will present at the following investor conferences.
-
San Diego-based Arcturus Therapeutics signed a strategic collaboration and licensing deal with CSL Seqirus to help develop and commercialize vaccines.